A Study of Bermekimab in Patients With Hidradenitis Suppurativa

Status Completed

Clinical Trial Summary

Phase 2 study of bermekimab in patients with moderate to severe Hidradenitis Suppurativa.

Clinical Trial Description

Phase 2, open label study of bermekimab in patients with moderate to severe Hidradenitis Suppurativa. The study is multicenter and will consist of two patient groups, each of which will receive a total of 13 X 400mg weekly subcutaneous injections of bermekimab: Group A (n=10) patients who have failed anti-TNF therapy, and Group B (n=10) patients who have had no prior treatment with biological agents that block TNF. Patients will be followed for 13 weeks to allow for assessment of safety and preliminary efficacy. Additionally, patients who had received the 200 mg weekly subcutaneous injections of bermekimab under the previous version of this protocol are eligible to begin receiving the 400 mg dose starting with his/her next scheduled visit, and for the remainder of his/her treatment plan. XBiotech owned bermekimab and sponsored and completed study prior to Dec 30, 2019. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03512275
Study type	Interventional
Source	Janssen Research & Development, LLC
Contact
Status	Completed
Phase	Phase 2
Start date	June 20, 2018
Completion date	January 14, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02904902` - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa	Phase 3
Completed	`NCT03628924` - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)	Phase 2
Not yet recruiting	`NCT05531747` - Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa	N/A
Recruiting	`NCT06028230` - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Phase 2
Completed	`NCT03275870` - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa	Phase 1/Phase 2
Completed	`NCT03248531` - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.	Phase 2
Withdrawn	`NCT04100083` - Spironolactone for Hidradenitis Suppurativa	Phase 4
Completed	`NCT00329823` - Etanercept in Hidradenitis Suppurativa	Phase 2
Recruiting	`NCT05710393` - Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Completed	`NCT04019041` - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa	Phase 2
Completed	`NCT05286567` - A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.	Phase 1
Withdrawn	`NCT03929835` - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa	Phase 2
Terminated	`NCT04325607` - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa	N/A
Terminated	`NCT03238469` - Microwave Ablation in Mild Axillary Hidradenitis Suppurativa	N/A
Completed	`NCT04449354` - HidraWear AX HS Study	N/A
Recruiting	`NCT06123429` - Mindfulness in Hidradenitis Suppurativa	N/A
Recruiting	`NCT05934825` - Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa	Phase 1/Phase 2
Recruiting	`NCT05635266` - A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting	`NCT06046729` - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Phase 2
Recruiting	`NCT04246372` - Tofacitinib for Immune Skin Conditions in Down Syndrome	Phase 2